drugset
drugset / Trial / NCT03066193

Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome

NCT03066193 ↗

Phase 2 Completed 17 enrolled Yale University Neurothera Labs Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an investigator-initiated proof of concept study with the purpose to examine the safety, tolerability and feasibility of Dronabinol (synthetic Δ9-THC) and PEA for the treatment of adults with Tourette syndrome.

Timeline

Start
2017-02-01
Primary completion
2018-06-28
Completion
2018-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 10 mg —
Subject Palmidrol Small molecule 400 mg —

Indications

Tourette syndrome